Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain. Under the EUA granted in February... Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:...
- Mechanism
- Curator reviewed
Etesevimab aims to neutralize SARS-CoV-2 by specifically binding to the virus' surface spike protein receptor binding domain. This high affinity binding then prevents SARS-CoV-2 from binding to the ACE2 host cell surface receptor. Etesevimab is currently being investigated against COVID-19.
- Primary indication
- Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at...Curator reviewed · 2 structured indications
- Code names
- CB6 · JS016 · LY-3832479 · LY-CoV016 · NP005 · WHO 11873
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Etesevimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account